STOCK TITAN

David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) reported insider dispositions. David Rodman reported multiple sales of Common Stock over January–March 2026, including a broker-assisted cashless exercise reported on 03/12/2026 covering 6,348 shares. The filing lists several prior dispositions in the three months before that date with individual sale dates and share counts.

Positive

  • None.

Negative

  • None.

Insights

Routine insider dispositions reported; timing and amounts are disclosed.

The filing lists a broker-assisted cashless exercise of 6,348 shares on 03/12/2026 and multiple prior sales in January–March 2026. These entries document transactions by a reporting person rather than corporate action.

Cash-flow treatment and any use of proceeds are not detailed in the excerpt; subsequent SEC filings would show further position context or plan disclosures.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Mineralys Therapeutics (MLYS) disclose in this Form 144?

The filing discloses reported dispositions of Common Stock by David Rodman, including a 6,348-share broker-assisted cashless exercise on 03/12/2026. It lists multiple prior sales with dates and share counts in January–March 2026.

How many shares were reported sold on 03/12/2026 in the MLYS Form 144?

The Form 144 lists a broker-assisted cashless exercise of 6,348 shares on 03/12/2026. The entry is shown under "Securities To Be Sold" with that exact share count and date.

Who is the reporting person that sold MLYS shares in the filing?

The reporting person named in the excerpt is David Rodman. Multiple sale entries in January–March 2026 are attributed to that individual with specific share counts and dollar amounts per transaction.

Does the Form 144 state how proceeds will be used?

The provided excerpt does not state any use-of-proceeds information. The entries list transaction types, dates, share counts, and dollar amounts but do not specify how proceeds were applied.

Are the prior sales in the past three months detailed in the filing?

Yes; the filing lists several prior dispositions by date with share counts and dollar amounts across January–March 2026, including transactions of 192,715, 70,037, and other share amounts shown alongside transaction dates.
Mineralys Therapeutics, Inc.

NASDAQ:MLYS

View MLYS Stock Overview

MLYS Rankings

MLYS Latest News

MLYS Latest SEC Filings

MLYS Stock Data

2.14B
75.18M
Biotechnology
Pharmaceutical Preparations
Link
United States
RADNOR